Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Non-small Cell Lung Cancer
Bronchioloalveolar Cancer

Interventions

DRUG: Gefitinib

Sponsor

Memorial Sloan Kettering Cancer Center